Key result
Adding argatroban to antiplatelets increases excellent 90-day functional outcomes by ~36% in acute ischemic stroke.
Why the study?
Many acute ischemic stroke patients experience early neurological deterioration despite standard antiplatelet therapy, and the efficacy and safety of argatroban as an adjunct remain to be clarified.
Does argatroban combined with antiplatelet therapy improve functional outcomes in acute ischemic stroke patients?
Meta-Analysis (n=10,108)
Does argatroban combined with antiplatelet therapy improve functional outcomes in acute ischemic stroke patients?
Argatroban combined with antiplatelet therapy improves functional recovery and reduces early neurological deterioration in acute ischemic stroke without increasing bleeding risks.
Answers are grounded in this paper and cite their sources.
Argatroban plus antiplatelets may improve functional outcomes and reduce END in AIS; supports adjunctive use with DAPT but leaves open need for large RCTs.
Acute ischemic stroke (AIS) is a major cause of disability and mortality worldwide. While antiplatelet therapy is standard for secondary prevention, many patients still experience early neurological deterioration (END). Argatroban, a direct thrombin inhibitor, can potentially limit thrombus progression and improve AIS's functional outcomes. This meta-analysis assessed the efficacy and safety of argatroban in combination with single (SAPT) or dual antiplatelet therapy (DAPT) compared to antiplatelets alone. Following PRISMA guidelines, a systematic search of PubMed, Scopus, and Web of Science was conducted until January 2025. Randomized controlled trials (RCTs) and cohort studies evaluating argatroban plus antiplatelets versus antiplatelets alone in AIS patients were included. The primary outcome was a 90-day modified Rankin Score (mRS) of 0-2. Secondary outcomes included mRS 0-1 and mRS 3-5 at 90 days, END, and National Institutes of Health Stroke Scale (NIHSS) improvement, stroke recurrence, intracranial hemorrhage (ICH), symptomatic intracranial hemorrhage (sICH), and mortality. We used the mean difference (MD) for continuous variables and odds ratio (OR) for dichotomous ones at 95% confidence intervals (CI) and a P-value of 0.05. A total of 14 studies (four RCTs and 10 cohort studies) were included. Compared to antiplatelets alone, argatroban significantly improved functional outcomes, increasing the incidence of mRS 0-2 (OR = 1.36 [95%CI: 1.05, 1.76, P = 0.02]) and mRS 0-1 (OR = 1.54 [95%CI: 1.08, 2.2, P = 0.02]) while reducing END (OR = 0.42 [95%CI: 0.21, 0.85, P = 0.02]). Argatroban was also associated with greater NIHSS score improvement (MD = - 0.52 [95%CI: - 0.89, - 0.15, P = 0.005]). No significant differences were observed in mRS 3-5, stroke recurrence, ICH, sICH, or mortality. Subgroup analysis indicated that argatroban combined with DAPT showed the greatest benefits. Argatroban combined with antiplatelet therapy improves functional recovery and reduces END without increasing bleeding risks. These findings support its use, particularly with DAPT, in mild to moderate AIS management. Further large-scale RCTs are needed to optimize dosing strategies and patient selection.
No takes yet. Share an insight, caveat, or question.
Moawad et al. (2025) conducted a meta-analysis in Acute ischemic stroke (n=10,108). Argatroban plus antiplatelet therapy vs. Antiplatelet therapy alone was evaluated on 90-day modified Rankin Score (mRS) of 0-2 (OR 1.36, 95% CI 1.05-1.76, p=0.02). Argatroban combined with antiplatelet therapy increased the incidence of excellent functional outcomes (mRS 0-2) at 90 days compared to antiplatelets alone in patients with acute ischemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: